Paul Szymanski

Paul Szymanski has extensive experience in the field of scientific research and development. Paul is currently working as a Principal Scientist at Metagenomi. Prior to this, they worked at 4D Molecular Therapeutics, where they held the role of Principal Scientist/Payload Development Group Leader. In this position, they led a team, constructed gene therapy expression vectors, and initiated the wet AMD gene therapy project. Before that, Paul worked at Intrexon Corporation as a Principal Scientist in the Immuno-Oncology Division, where they led multiple projects and played a key role in the acquisition of Medistem by Intrexon. Paul also worked at Perseid Therapeutics as a Staff Scientist III, where they led several protein engineering projects. Additionally, Paul has experience working at Bayer HealthCare Pharmaceuticals, Berlex Biosciences, and GeneMedicine, Inc., where they contributed to the development of various technologies and therapies.

Paul Szymanski holds a Ph.D. in Cell and Molecular Biology from the Roswell Park Graduate Division of State University of New York at Buffalo. Paul also obtained a B.S. in Biology from Rensselaer Polytechnic Institute. Prior to their undergraduate studies, Paul attended Alden Central High School.